JP2022516662A5 - - Google Patents
Info
- Publication number
- JP2022516662A5 JP2022516662A5 JP2021539637A JP2021539637A JP2022516662A5 JP 2022516662 A5 JP2022516662 A5 JP 2022516662A5 JP 2021539637 A JP2021539637 A JP 2021539637A JP 2021539637 A JP2021539637 A JP 2021539637A JP 2022516662 A5 JP2022516662 A5 JP 2022516662A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- individual
- pharmaceutical composition
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789937P | 2019-01-08 | 2019-01-08 | |
| US62/789,937 | 2019-01-08 | ||
| PCT/US2020/012783 WO2020146529A1 (en) | 2019-01-08 | 2020-01-08 | Methods of treating conditions related to the s1p1 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516662A JP2022516662A (ja) | 2022-03-01 |
| JP2022516662A5 true JP2022516662A5 (cg-RX-API-DMAC7.html) | 2023-01-20 |
Family
ID=69467760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539637A Ceased JP2022516662A (ja) | 2019-01-08 | 2020-01-08 | S1p1受容体に関連する状態を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220142977A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3908276B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022516662A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102958419B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113874009A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020206700A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3124701A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284114A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021008263A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020146529A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
| KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体に関連する状態を治療する方法 |
| ES2951870T3 (es) * | 2018-10-03 | 2023-10-25 | Arena Pharm Inc | Etrasimod para su uso en procedimientos para el tratamiento de la esclerodermia |
| MX2021008263A (es) | 2019-01-08 | 2021-10-13 | Arena Pharm Inc | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. |
| WO2025177319A2 (en) * | 2024-02-22 | 2025-08-28 | Msn Laboratories Private Limited, R&D Center | Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| PL2342205T4 (pl) * | 2008-08-27 | 2016-12-30 | Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych | |
| EP2528894A1 (en) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6047203B2 (ja) * | 2015-02-20 | 2016-12-21 | セルセウティックス コーポレイション | 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬 |
| MX2021008263A (es) | 2019-01-08 | 2021-10-13 | Arena Pharm Inc | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. |
-
2020
- 2020-01-08 MX MX2021008263A patent/MX2021008263A/es unknown
- 2020-01-08 AU AU2020206700A patent/AU2020206700A1/en not_active Abandoned
- 2020-01-08 US US17/421,299 patent/US20220142977A1/en not_active Abandoned
- 2020-01-08 KR KR1020217024973A patent/KR102958419B1/ko active Active
- 2020-01-08 CN CN202080018255.4A patent/CN113874009A/zh active Pending
- 2020-01-08 CA CA3124701A patent/CA3124701A1/en active Pending
- 2020-01-08 EP EP20703633.6A patent/EP3908276B1/en active Active
- 2020-01-08 WO PCT/US2020/012783 patent/WO2020146529A1/en not_active Ceased
- 2020-01-08 JP JP2021539637A patent/JP2022516662A/ja not_active Ceased
- 2020-01-08 CN CN202411067321.3A patent/CN118976023A/zh active Pending
-
2021
- 2021-06-17 IL IL284114A patent/IL284114A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2505944B2 (ja) | (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| JP4938905B2 (ja) | 選択的s1p1レセプターアゴニストの投与法 | |
| CN111132675B (zh) | 胆汁淤积性瘙痒的治疗 | |
| KR101801864B1 (ko) | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 | |
| US20170216212A1 (en) | Tapentadol compositions | |
| JP2022511788A5 (cg-RX-API-DMAC7.html) | ||
| AU2009242113A1 (en) | Combination compositions for treating Alzheimer disease and related disorders with zonisamide and acamprosate | |
| JP5208473B2 (ja) | アゼラスチンと抗コリン薬を含有する医薬組成物 | |
| JP2022550919A5 (cg-RX-API-DMAC7.html) | ||
| CN1210465A (zh) | 治疗方法和药物组合物 | |
| WO2005094832A1 (en) | Compositions comprising meloxicam | |
| JP2023509698A5 (cg-RX-API-DMAC7.html) | ||
| CN115702143A (zh) | 治疗系统性硬化症的方法 | |
| WO2021207349A1 (en) | Prevention and treatment of virial infections | |
| JP2026510948A (ja) | 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法 | |
| TWI282735B (en) | Combination and pharmaceutical formulation for the treatment of HBV infection | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| WO2018232260A1 (en) | Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| CN1263465A (zh) | 利用选择性5-羟色胺再摄取抑制剂治疗和预防心脏病 | |
| RU2021123406A (ru) | Способы лечения состояний, связанных с рецептором s1p1 | |
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| JP2009007332A (ja) | アゼラスチン類とエフェドリン類を含有する医薬組成物 | |
| JP2010111667A (ja) | フェキソフェナジン又はエバスチンを含有する鎮咳及び/又は去痰のための医薬組成物 | |
| JPH04282313A (ja) | 血圧降下剤 |